Furthermore, a panel of five genes including FASN (ACOT8/ACSL5/FASN/HMGBCS2/SCD1) has been reported to display a improved prognostic performance than validated clinical risk scales, and it is applicable for early discovery of CRC and tumor recurrence (112). This evidence concerns the gene SCD and colorectal carcinoma.